IVERIC bio is a biopharmaceutical company that concentrates on developing innovative treatments for retinal diseases. Their drugs in the clinical trial phases include the C5 inhibitor Zimura for AMD and GA, while STAR or OPH2005 treats LCA10 and STGD1, and IC drugs treat rhodopsin-mediated autosomal dominant retinitis pigmentosa and other age-related retinal diseases. The company also works on discovering new treatments for various types of IRDs.